Call your HCP or get emergency medical help right away if you have any of the following symptoms of an allergic reaction: swelling of the face, mouth, tongue or throat, or trouble breathing. This can happen within hours to days after using Aimovig ®. Allergic reactions, including rash or swelling can happen after receiving Aimovig ®. What are possible side effects of Aimovig ®?Īimovig ® may cause serious side effects, including: Tell your HCP about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements. Please see Aimovig ® full Prescribing Information.Do not use Aimovig ® if you are allergic to erenumab-aooe or any ingredients in Aimovig ®.īefore starting Aimovig ®, tell your healthcare provider (HCP) about all your medical conditions, including if you are allergic to rubber or latex, pregnant or plan to become pregnant, breastfeeding or plan to breastfeed. Monitor patients treated with Aimovig ® for new-onset hypertension, or worsening of pre-existing hypertension, and consider whether discontinuation of Aimovig ® is warranted if evaluation fails to establish an alternative etiology.Īdverse Reactions: The most common adverse reactions in clinical studies (≥ 3% of Aimovig ®-treated patients and more often than placebo) were injection site reactions and constipation. Aimovig ® was discontinued in many of the reported cases. In the majority of the cases, the onset or worsening of hypertension was reported after the first dose. Hypertension may occur at any time during treatment but was most frequently reported within seven days of dose administration. There were cases requiring pharmacological treatment and, in some cases, hospitalization. Many of the patients had pre-existing hypertension or risk factors for hypertension. Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of Aimovig ® in the postmarketing setting. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications. Monitor patients treated with Aimovig ® for severe constipation and manage as clinically appropriate. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies. Aimovig ® was discontinued in most reported cases. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. ![]() There were cases that required hospitalization, including cases where surgery was necessary. If a serious or severe reaction occurs, discontinue Aimovig ® and initiate appropriate therapy.Ĭonstipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig ® in the postmarketing setting. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig ® in post marketing experience. Reactions have included anaphylaxis and angioedema. Important Safety InformationĬontraindication: Aimovig ® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Aimovig ® (erenumab-aooe) is indicated for the preventive treatment of migraine in adults.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |